Bluebird bio, Inc., a clinical-stage company committed to T cell-based immuno-therapies, today announced the pricing of an underwritten public offering of 2,941,176 shares of its common stock at a public offering price of $170.00 per share, for the gross proceeds of $500 Million.
The firm would use the proceeds of this offering primarily to advance its immune-oncology programs, and commercial launching in Europe.
View the full release here.